2025 SEAAIS 80th Annual Meeting

White Sulphur Springs, WV US
October 23, 2025 to October 26, 2025

The Southeastern Allergy, Asthma & Immunology Society's annual conference is focused on the field of allergy, asthma, and immunology.  It is directed to physicians, physician assistants, nurse practitioners and administrators.  The purpose is to engage the audience through oral didactic presentations followed by group discussions.  Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board.  Case presentations are often utilized to solidify the objectives covered in each presentation.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Southeastern Allergy, Asthma & Immunology Society (SEAAIS). The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14.50 contact hours.

No commercial support was received for this activity.

Target Audience

Physicians
Physician assistants
Nurse practitioners
Administrators

Learning Objectives

At the conclusion of this Activity learners should be able to…

  1. Appreciate that RV can produce an asymptomatic) chronic RV infection in preschool children with problematic wheeze and to understand that indolent RV produces a bronchoalveolitis with activated PMNs and macrophages.
  2. Implement anaphylaxis preparedness in teen-age children and discuss the role of SDM in food allergy/anaphylaxis management, and identify when to consider changing treatment strategies.
  3. Recognize the clinical presentation and diagnostic criteria for Mast Cell Activation Syndrome (MCAS) using current consensus guidelines to differentiate it from other allergic, immunologic, and gastrointestinal disorders. Evaluate and implement evidence-based approaches to the management of MCAS, including pharmacologic strategies and individualized patient care plans.
  4. Understand HAE diagnosis and review current treatment options.
  5. Apply accurate coding strategies to common clinical scenarios in allergy and immunology and identify common coding errors and documentation pitfalls in allergy/immunology billing and implement best practices to reduce claim denials, improve audit readiness, and enhance revenue cycle efficiency.
  6. Learn that T2 high inflammation reduces natural immunity to staph and understand the theoretical ability of T2 targeting therapies to amelior chronic staph in nasal polyps.
  7. Discuss current government affairs and learn how the joint commission council is working to address issues that may affect the practicing allergist/immunologist.
  8. Understand safety differences between sublingual and subcutaneous immunotherapy and identify current and future potential practice parameter safety recommendations.
  9. Discuss burnout among physicians and other healthcare workers and how to prepare for a career change.
  10. Recognize and manage the full spectrum of clinical reactions during oral food challenges, from mild urticaria to severe anaphylaxis, including immediate intervention strategies.
  11. Learn key updates in CIU and novel therapies on the horizon to improve patient outcomes and integrate best practices and standardized protocols in conducting OFCs to improve diagnostic accuracy and patient outcomes, while ensuring staff preparedness and safety.
  12. Evaluate current evidence-based management strategies for AERD, including aspirin desensitization protocols, biologic therapies, and adjunctive treatments and implement comprehensive patient education and multidisciplinary care approaches to optimize long-term outcomes and quality of life for patients with AERD.
  13. Learn how and when to perform punch and shave biopsies, including  proper techniques, procedural coding, selection of appropriate patients for each type of biopsy, selection of an appropriate lesion and site for the highest diagnostic yield, a review of the materials and transport media and how to interpret the report from the dermatopathologist to aid in the diagnosis and treatment of patients.
  14. Understand the role of ABAI in the board certification community and identify opportunities for allergy-immunology education and certification research.
  15. Develop and refine EoE screening strategies and review the landscape of longitudinal assessments in EoE.
  16. Apply updated evidence-based guidelines for the stepwise management of chronic urticaria, including optimized antihistamine use and indications for advanced therapies like omalizumab and cyclosporine, and incorporate patient-centered approaches to assess and address quality-of-life impacts, including the use of validated disease activity scores and strategies for psychosocial support.
  17. Identify the spectrum of adverse reactions associated with biologic therapies used in allergy and immunology, including acute infusion reactions, delayed hypersensitivity, and immunogenicity-related effects and differentiate between true allergic reactions and non-allergic infusion-related adverse events to guide appropriate management and continuation of therapy.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 14.50 AMA PRA Category 1 Credit™
  • 14.50 Attendance
  • 14.50 CBRN
Course opens: 
10/23/2025
Course expires: 
12/31/2025
Event starts: 
10/23/2025 - 7:00am CDT
Event ends: 
10/26/2025 - 11:00am CDT
Add to calendar: 
Rating: 
5

2025 SEAAIS Annual Meeting
The Greenbrier | White Sulphur Springs, WV
October 23 - 26, 2025

Friday, October 24
ALL CME SESSIONS WILL TAKE PLACE IN CHESAPEAKE ROOM

7:00 – 8:00 AM    BREAKFAST IN EXHIBITOR HALL – COLONIAL HALL
   
8:00 – 8:05 AM    Welcome and Opening Remarks, Lee S. Clore, Jr., MD, Executive Secretary-Treasurer
8:05 – 8:45 AM    Staph aureus and Nasal polyps: A Vicious Circle and What You Can Do About It, Larry Borish, MD
8:45 – 9:45 AM    PBL: A Challenging Case of a Teenager with Recurrent Anaphylaxis Due to Food Allergy, Don Bukstein, MD, Ray Davis, MD, Allen Meadows, MD, Russell Settipane, MD

9:45 – 10:25 AM    BREAK IN EXHIBITOR HALL - COLONIAL HALL
   
10:25 – 10:45 AM    Therapeutic Options for an Asthmatic Teenager with Recurrent Anaphylaxis Due to Food Allergy, Russell Settipane, MD
10:45 – 11:25 PM     Fear to Freedom: Treating Food Allergies Today, Sunena Chhabra Argo, MD
11:25 – 12:05 PM    Mast Cell Activation Syndrome:  Be Not Afraid, John Fahrenholz, MD
12:05 – 12:15 PM    Question & Answer Session, Lee S. Clore, Jr., MD, Executive Secretary-Treasurer

12:15 – 1:00 PM    LUNCH IN EXHIBITOR HALL - COLONIAL HALL    

1:00 – 1:40 PM    Prophylaxis vs. Therapeutic Management Strategies for Hereditary Angioedema, James Tracy, DO
1:40 – 2:20 PM    Coding Update: Practice Management Symposium, Wes Sublett, MD, Brought to you by the American College of Allergy, Asthma & Immunology  
2:20 – 2:30 PM    Question & Answer Session, Lee S. Clore, Jr., MD, Executive Secretary-Treasurer
2:30 – 3:00 PM    BUSINESS MEETING – Members Only Please, Lee S. Clore, Jr., MD, Executive Secretary-Treasurer

Saturday, October 25
ALL CME SESSIONS WILL TAKE PLACE IN CHESAPEAKE ROOM

7:00 – 8:00 AM    BREAKFAST IN EXHIBITOR HALL – COLONIAL HALL 
 
8:00 – 8:05 AM    Welcome & Opening Remarks     J. Allen Meadows, MD, President
8:05 – 8:45 AM    Indolent Rhinovirus Infection in Preschool Children with Problematic Wheeze, Larry Borish, MD
8:45 – 9:25 AM    Government Affairs Update - Practice Management Symposium, Travis Miller, MD, Brought to you by the American College of Allergy, Asthma & Immunology
9:25 – 10:05 AM    Where Are We with Allergen Extracts and Safety of Allergen Immunotherapy?, Mike Nelson, MD
10:05 – 10:15 AM    Question & Answer, J. Allen Meadows, MD, President

10:15 – 10:45 AM    BREAK IN EXHIBITOR HALL - COLONIAL HALL

10:45 – 11:25 AM    Don’t Be Afraid to Pivot:  Changing your Career Rather Than Abandoning It, Melinda Rathkopf, MD
11:25 – 11:35 AM    Fellow Presentation: Genotype Without Severe Phenotype:  Stable Clinical Course of XMEN Disease in Two Siblings, Marlin Hana, MD, Virginia Commonwealth University
11:35 – 11:45 AM    Fellow Presentation: Specificity of A2B Receptor Activation by Adenosine in Human Airway Epithelial Cells, Maria Amelia Perozo, MD, University of Virginia 
11:45 – 12:25 PM    From Hives to Hypotension: Navigating Oral Food Challenges, Amy CaJacob, MD John A. Yarbrough, MD Memorial Lecture:

12:25 – 1:05 PM    LUNCH IN EXHIBITOR HALL - COLONIAL HALL    
 
1:10 – 1:50 PM    Update on Aspirin Exacerbated Respiratory Disease,  David Lang, MD
1:50 – 2:00 PM    Question and Answer Session, J. Allen Meadows, MD, President
2:30 – 4:00 PM    Hands on Workshop:  Making the Cut; Shave vs. Punch, David Weldon, MD, Marcella Aquino, MD, Sharon Jacob, MD
                             Located in Eisenhower A; Entry by Ticket Only

Sunday, October 26
ALL CME SESSIONS WILL TAKE PLACE IN CHESAPEAKE ROOM

8:15 – 8:20 AM    Welcome & Opening Remarks, Amy CaJacob, MD, 1st Vice President
8:20 – 9:00 AM    Future of ABMS & ABAI Board Certification, Mike Nelson, MD
9:00 – 9:40 AM    The Great Masticators: Updates in Eosinophilic Esophagitis, Nick CaJacob, MD
9:40 – 10:20 AM    Chronic Urticaria:  Scratching Below the Surface, David Lang, MD
10:20 – 11:00 AM    Contact Dermatitis and Delayed Type Hypersensitivity Reactions, Steve Dorman, MD
11:00 – 11:10 AM    Questions & Closing Remarks, Amy CaJacob, MD, 1st Vice President
 

The Greenbrier
101 Main Street West
White Sulphur Springs, WV 24986
United States

All relevant financial relationships with ineligible companies have been mitigated.

Larry Borish, MD, Speaker
Consultant:  AstraZeneca, Sanofi
Independent Contractor:  Regeneron
 
Don Bukstein, MD, Speaker
Consultant: AstraZeneca, Grifols, Kalvista
Speaker: Sanofi Regeneron
 
Lee S. Clore, Jr., MD, Planner, Moderator
Advisor:  Incyte
Speaker:  AstraZeneca, Eli Lilly, GSK, Novartis, Pharming, Sanofi Regeneron
Research – AstraZeneca, Eli Lilly, GSK, Novartis, Sanofi Regeneron, Escient, OM Pharma

Ray Davis, MD, Speaker
Consultant:  AstraZeneca, Grifols, Kalvista, Sanofi Regeneron

Steve Dorman, MD, Speaker
Advisor:  Takeda
Consultant:  AstraZeneca, Takeda
Researcher:  Takeda

John Fahrenholz, MD, Speaker
Advisor:  Blueprint Medicines, Cogent
Researcher:  Blueprint Medicines, Cogent 

David Lang, MD, Planner, Moderator, Speaker
Consultant:  Celldex, Genentech, Novartis
Speaker:  Novartis

J. Allen Meadows, MD, Planner, Moderator, Speaker
Consultant:  Sanofi
Speaker:  Sanofi
Consultant: Aerin Medical
Research:  Aerin Medical
 
Mike Nelson, MD, Speaker
Researcher:  AstraZeneca, Sanofi
 
Russell Settipane, MD, Speaker
Advisor:  Abbvie, AstraZeneca, Biocryst, DBV Technologies, GSK, Kalvista, Pharming
Speaker:  Abbvie, AstraZeneca, Biocryst, GSK, Grifols, Pharming, Pfizer, Regeneron, Sanofi
Researcher:  Biocryst, Regeneron

Wesley Sublett, MD, Speaker
Researcher: ALK, AstraZeneca, Amgen, DBV, Aimmune, BioCryst, Evidera, GSK, LEO, Novartis, Octapharma, Sanofi Regeneron, Target, TEVA
Advisor: AstraZeneca, Amgen, Genentech, Byrn Pharma, Dermavant, Genentech, Pfizer, Regeneron, Sanofi
Speaker: AstraZeneca, Amgen, Genentech, Sanofi, Regeneron


The following have no relevant financial relationships with ineligible companies to disclose:

Marcella Acquino, MD, Speaker
Sunena Chhabra Argo, MD, Speaker
Amy CaJacob, MD, Speaker, Moderator
Nick CaJacob, MD, Speaker
J. Trent Ellenburg, DO, Planner
Marlin Hana, MD, Speaker
Sharon Jacob, MD, Speaker
Travis Miller, MD, Speaker
Jean Owen, MBA, Planner
Maria Amelia Perozo, MD, Speaker
Melinda Rathkopf, MD, Speaker
James Tracy, DO, Speaker

Available Credit

  • 14.50 AMA PRA Category 1 Credit™
  • 14.50 Attendance
  • 14.50 CBRN
Please login or create an account to take this course.